Clinical Trials Logo
  1. Home
  2. Mixed Dyslipidemia
  3. NCT06204380
  4. Details
NCT06204380 Clinical Trial

An Observational Study on the Identification of Prescription Patterns of STAFEN Cap

Mixed Dyslipidemia Clinical Trial

Official title:
An Observational Study on the Identification of Prescription Patterns of STAFEN Cap., Changes in Blood Lipid Concentration, and Statin-related Muscle Symptoms in Korean Patients With Mixed Dyslipidemia

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06204380
Other study ID # HL-STAF-401
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 21, 2021
Est. completion date November 30, 2024

Study information
Verified date January 2024
Source Hanlim Pharm. Co., Ltd.
Contact Heebaek Park
Phone 01055279616
Email thyroid62@hanmail.net
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

An observational study on the identification of prescription patterns of STAFEN Cap., changes in blood lipid concentration, and statin-related muscle symptoms in Korean patients with mixed dyslipidemia

Description:

This study aims to observe the effectiveness of STAFEN capsule such as changes in blood lipid concentration and safety including statin-related muscle symptoms, and prescription patterns under daily clinical treatment in patients who have been prescribed STAFEN capsules for the treatment of complex dyslipidemia.

Recruitment information / eligibility
Status Recruiting
Enrollment 4000
Est. completion date November 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Adults over 19 years of age 2. A patient diagnosed with mixed dyslipidemia 3. A patient who was first prescribed a STAFEN cap. for the purpose of treating mixed dyslipidemia according to the clinician's judgment 4. A patient who voluntarily agreed in writing to this study Exclusion Criteria: 1. Pregnant women, lactating women, or those planning to conceive 2. A person who is prohibited from administering the STAFEN cap. under the permit 3. If the person in charge of other clinical studies and the person in charge deems it inappropriate to be the subject of this clinical study

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Delphoe Clinic Gangneung-si

Sponsors (1)
Lead Sponsor Collaborator
Hanlim Pharm. Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Target triglyceride rate at 6 months of STAFEN capsule prescription compared to baseline Target triglyceride rate at 6 months of STAFEN capsule prescription compared to baseline at 6 months of STAFEN capsule prescription compared to baseline
See also
  Status Clinical Trial Phase
Completed NCT04998201 - Study of ARO-APOC3 in Adults With Mixed Dyslipidemia Phase 2
Not yet recruiting NCT03648788 - A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Recruiting NCT05399992 - Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD
Withdrawn NCT05798390 - Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Completed NCT01256476 - Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia Phase 4
Completed NCT00171236 - Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT00487591 - An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia Phase 4
Terminated NCT03433755 - Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia Phase 3
Completed NCT02739984 - Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Phase 3
Not yet recruiting NCT06386419 - A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Phase 4
Terminated NCT01335997 - Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) Phase 3
Completed NCT00300456 - Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Phase 3
Completed NCT00300469 - Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Phase 3
Completed NCT00300482 - Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood Phase 3
Recruiting NCT06314919 - A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
Terminated NCT01274559 - Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Phase 3
Active, not recruiting NCT04832971 - Study of ARO-ANG3 in Adults With Mixed Dyslipidemia Phase 2
Completed NCT00491530 - A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia Phase 3
Completed NCT00136799 - Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia Phase 3